Contract analysis

I. Executive Summary The purpose of this memorandum is to analyze the intercompany license agreement (the "License Agreement") between Penterra Pharmaceuticals Corp. ("PPC") and Penterra Biopharma International DAC ("PBI") covering legacy pharmaceutical compounds — specifically, pre-2012 vintage intellectual property that was not included in the qualified cost-sharing arrangement ("CSA") between PPC and PBI — for com

II. Background A. Parties to the License Agreement Licensor: Penterra Pharmaceuticals Corp. ("PPC") PPC is a corporation organized under the laws of the State of Delaware, with its principal headquarters located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." For its fiscal year ending December 31, 2020, PPC report

III. Applicable Legal and Regulatory Framework A. IRC § 482 — General Principles

Section 482 of the Internal Revenue Code authorizes the Secretary of the Treasury to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasi

Section 1.482-4(a): Commensurate-with-Income Standard. Treas. Reg. § 1.482-4(a) provides that the arm's-length consideration for the transfer of intangible property must be "commensurate with the income attributable to the intangible." This standard, enacted as part of the Tax Reform Act of 1986, imposes a heightened requirement that the royalty rate for intangible property transfers reflect the actual income generat

Section 1.482-4(b): Specified Methods. The regulations identify four categories of methods for determining the arm's-length consideration for intangible property transfers:

1. The Comparable Uncontrolled Transaction ("CUT") method, set forth in § 1.482-4(c);

2. The Comparable Profits Method ("CPM"), set forth in § 1.482-5;

3. The Profit Split Method, set forth in § 1.482-6; and

4. Unspecified methods, as permitted under § 1.482-4(d).

Section 1.482-4(c): The CUT Method. The CUT method determines an arm's-length royalty rate by reference to the amount charged in a comparable uncontrolled transaction — that is, a transaction between unrelated parties involving the transfer of comparable intangible property under comparable circumstances. The CUT method is the most direct and reliable method for testing a royalty rate when sufficiently comparable unc

Section 1.482-4(d): Periodic Adjustment Rule. The periodic adjustment rule permits the IRS to adjust royalty rates in subsequent years if the actual results of the controlled transaction diverge significantly from the projections used to set the royalty rate at inception. This rule gives effect to the "commensurate with income" standard by ensuring that royalty rates continue to reflect the economic reality of the in

Section 1.482-4(f)(2): Definition of Intangible Property. The regulations define intangible property broadly to include patents, inventions, formulae, processes, designs, patterns, know-how, copyrights, literary, musical, or artistic compositions, trademarks, trade names, brand names, franchises, licenses, contracts, methods, programs, systems, procedures, campaigns, surveys, studies, forecasts, estimates, customer l

Section 6662(e) of the Internal Revenue Code imposes a 20% accuracy-related penalty in the case of a substantial valuation misstatement in connection with a Section 482 transfer pricing adjustment. A substantial valuation misstatement exists if the transfer price claimed by the taxpayer is 200% or more (or 50% or less) of the correct price, and the net Section 482 transfer pricing adjustment for the taxable year exce

IV. Best Method Analysis — Selection of CUT Method for Legacy IP Royalty A. Why CUT Is the Best Method The CUT method is the best method for evaluating the arm's-length character of the 4.5% royalty rate under the License Agreement. This conclusion is based on the following considerations. First, the legacy IP license involves a straightforward royalty-for-license structure — PPC, as the licensor, grants PBI an exclu

V. Comparability Analysis — Application of CUT Method A. Identification of Comparable Uncontrolled Transactions To support PPC's defense of the 4.5% royalty rate, Calderwood & Harkness has engaged Whitmore Valuation Group LLC to perform an independent economic analysis, including a CUT benchmarking study for the legacy IP royalty. Whitmore Valuation Group has been retained under a Kovel arrangement to ensure that its

1. Nature of Intangible Property. All 14 CUT comparables involve pharmaceutical intellectual property, including patents, know-how, regulatory dossiers, and related IP rights for marketed or late-stage pharmaceutical compounds. The intangible property in the CUT comparables is of a similar type to the legacy compounds licensed under the License Agreement — namely, pharmaceutical IP covering marketed products with est

2. Contractual Terms. The CUT comparables involve exclusive territorial licenses with royalty-based compensation structures — consistent with the License Agreement between PPC and PBI. Adjustments were considered for differences in sub-licensing rights, milestone payment provisions, minimum royalty requirements, and other contractual features that could affect the effective royalty rate. Where material differences we

3. Geographic Scope. The selected CUT comparables involve licenses for international territories, including ex-U.S., ex-Americas, and global (excluding the licensor's home market) territorial grants. This geographic scope is comparable to PBI's non-Americas territory under the License Agreement. CUT comparables limited to the U.S. market were excluded from the analysis, as the U.S. pharmaceutical market has distinct

4. Functions Performed / Risks Assumed. In each of the 14 CUT comparables, the licensee performs substantial commercialization functions, including marketing, distribution, pricing, regulatory maintenance, and medical affairs. The licensees in the CUT comparables also assume commercial risk associated with the exploitation of the licensed products, including demand risk, pricing risk, regulatory risk, and credit risk

5. Economic Conditions. The CUT comparables were executed between 2005 and 2020, a period that encompasses a range of economic conditions and pharmaceutical industry dynamics broadly comparable to those prevailing during the term of the License Agreement. Where differences in economic conditions were identified that could materially affect comparability (e.g., differences in market maturity, competitive intensity, or

6. Product Maturity. As noted above, the legacy compounds licensed under the License Agreement are mature products with declining revenue trajectories. This product maturity characteristic is a critical comparability factor, because the expected future income attributable to a mature, declining product is lower than the expected future income attributable to a growth-stage or blockbuster product, and this difference

VI. Analysis of Key Terms of the Legacy IP License Agreement A. Royalty Rate (4.5%) The 4.5% royalty rate was established at the time of PBI's formation in 2012 based on a benchmarking study conducted by Crestfield & Associates LLP. The study identified comparable uncontrolled pharmaceutical license agreements and determined that a 4.5% royalty rate was within the arm's-length range for the licensing of mature pharma

VII. Anticipated IRS Challenge and Rebuttal A. Expected IRS Position Based on examination trends in the pharmaceutical industry, the known focus areas of the LB&I division's transfer pricing practice, and the scope and nature of the initial IDR requests issued by Exam Team LB&I-NE-TP-2022-00641, we anticipate that the IRS will challenge the 4.5% legacy IP royalty rate on the following grounds:

1. The royalty rate is below the arm's-length range. The IRS is likely to argue that 4.5% is below the arm's-length range for pharmaceutical IP licenses and that the rate should be substantially higher — potentially 11.0% or more. This argument would be based on the IRS's own selection of CUT comparables, which we anticipate will include pharmaceutical licensing agreements involving growth-stage or blockbuster compou

2. Higher-rate CUT comparables. The IRS may cite pharmaceutical licensing agreements involving high-value, growth-stage, or blockbuster pharmaceutical compounds and argue that these agreements are comparable to PPC's legacy compound portfolio. If the IRS selects CUT comparables at higher rates without properly accounting for the fundamental differences between growth-stage/Blockbuster IP and mature, declining-value l

3. Challenge to PPC's CUT selection criteria. The IRS may argue that PPC's CUT selection criteria are too narrow or that the comparability adjustments applied by Whitmore Valuation Group are insufficient. Specifically, the IRS may contend that PPC's focus on mature, declining-revenue products as the basis for CUT selection improperly excludes relevant comparables at higher rates. If the IRS were to propose an 11.0% r

1. CUT Comparability Deficiency in IRS Selections. Any CUT comparables selected by the IRS at an 11.0% royalty rate almost certainly involve growth-stage or blockbuster pharmaceutical compounds with fundamentally different risk/reward profiles than PPC's declining legacy compound portfolio. Growth-stage and blockbuster compounds typically exhibit strong revenue growth trajectories, significant remaining patent life,

2. Product Lifecycle Stage. The product lifecycle stage of the legacy compounds is the single most important comparability factor in this analysis. The legacy compounds are mature, declining-revenue products that are approaching or have already passed the peak of their commercial potential. Higher-rate CUT comparables typically involve IP with significant growth potential, pipeline expansion value, or blockbuster sta

3. PBI's Functions and Risks. PBI performs substantial and meaningful commercialization functions in the non-Americas territory, including regulatory maintenance across 68 country markets (at a cumulative cost of €47.2 million over 2017–2020), independent pricing and commercial strategy, supply chain management, medical affairs, and distribution. PBI also employs 185 people and maintains significant operational infra

4. Arm's-Length Range Compliance. PPC's 4.5% royalty rate falls within the interquartile range of 3.1% to 6.8% established by 14 reliable CUT comparables. Under Treas. Reg. § 1.482-1(e)(2), no adjustment is warranted when the tested price falls within the arm's-length range. The IRS cannot simply propose an alternative rate without first establishing